Recommended

Find out more on ‘AI & Informatics: Drug discovery and development’ in our exclusive report
Download your complimentary copy of our latest digital journal
Free membership: sign up today to access all of our exclusive content
Hear from industry leaders in our upcoming webinars – reserve your place today!
article

Expert view: Advances in NGS technology

2
SHARES

The multiplex and high-throughput capabilities of next-generation sequencing (NGS) allow researchers to study an immense number of DNA/RNA molecules per run, bringing opportunities to study biological or clinical research questions that could not be addressed before…

The most recent examples of advances in NGS technology include:

  • Reconstructing immuno-repertoire from a large diversity of immune cells
  • Detecting and studying clonality and evolution of tumours from cell-free DNA (cfDNA) and cell-free RNA (cfRNA) in blood, or intact cells from highly clonal tumours like AML
  • Reconstructing metagenomes and microbiomes for association with a disorder or discovery of unknown pathogens.

Enabling researchers to effectively utilise NGS tools to lift the boundaries of current understanding to new levels is one of the biggest opportunities in this field.

Recent innovations

Most of the recent innovations have evolved around simplifying usage of NGS technology and making it more robust. As this technology is increasingly leveraged to gain rapid and in-depth insights, the NGS market will continue to deliver improvements in automation, complete workflow applications, services, and analytical solutions. This will help with developing the future clinical NGS market, which could reach its inflection point in the next five years.

Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development. 

In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future. 

Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.

FREE DOWNLOAD HERE

Also featured in this NGS In-Depth Focus:

NGS: empowering infectious disease research beyond reality
Pushpanathan Muthuirulan (National Institutes of Health), Pooja Sharma (Catholic University of America)

How next-generation sequencing is opening the door for drug discovery
Kim Judge (Wellcome Trust Sanger Institute)

 
Share via
Share via